2025-05-22-Bernstein-诺和诺德（NOVOB）_快速解读诺和诺德对抗复方药房的另一个角度-_Wegovy的更低入门价格_12页_721kb

Quick Take Summary: Novo Nordisk

Key Insights

• Novo Nordisk is implementing a new pricing strategy for Wegovy (semaglutide) by offering a first-month price of $199, challenging compounding pharmacies that sell cheaper, unapproved versions.
• This move targets the US obesity market, where compounding pharmacies account for 30% of the market, with semaglutide making up 80% of these products.
• The company is pursuing legal action against compounding pharmacies through over 120 lawsuits, while also launching a new advertising campaign to promote FDA-approved treatments.
• Investment rating remains Market-Perform, with a price target of DKK 620.00 and an estimated 36% upside.

Investment Implications

• Despite short-term volatility due to CEO departure and competitive pressures, Novo Nordisk expects above-sector earnings growth driven by obesity market opportunities.
• Potential risks include competition from Lilly's oral semaglutide and other drugs, uncertain prescription recovery, and low visibility on pricing changes.
• Key catalysts to watch: Lilly's orforglipron data, US prescription trends post-compounding ban, Amycretin phase III decision, and CagriSema trials.

Valuation and Risks

• Current valuation: Trading at 15x 2025 earnings estimate, with a P/E ratio of 16.0x.
• Upside factors: Strong oral semaglutide success, positive US demand; downside risks: Amycretin failure, negative impact from US drug pricing, and delayed CagriSema differentiation.
• Market performance volatility anticipated, with catalysts expected in 2025 to influence stock movement.